Sofinnova Partners has made good money in three areas it says are considered "cardinal sins" among LPs these days: venture, life sciences and Europe. It's now unveiled its first fund with a focus on all three, the €240 million ($309.8 million) Sofinnova Capital VII.

The firm's first fund closed in April 1989 at what now would be €38 million and was split evenly between the life sciences and IT.